Diagnosing overactive immune response in ICU patients
Part of Digestive system clinical trials.
This study is looking at patients who were in the intensive care unit and showed signs of a condition called HLH, where the immune system becomes overactive. Researchers want to understand how these signs were diagnosed and managed in the ICU.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were 18 or older when in the ICU.
- You were in the ICU at Hautepierre Hospital, Strasbourg, between January 2014 and December 2024.
- You had at least three signs of HLH: very high ferritin, high triglycerides, or low blood counts (low white blood cells, low platelets, or low hemoglobin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how to treat a severe, whole-body immune overreaction (“hemophagocytosis”) in adults who are critically ill. You might be considered if blood counts are low (white blood cells and platelets) and if you are already receiving a growth-factor medicine (rhG-CSF).
This study is for people with hemophagocytic lymphohistiocytosis (HLH), a condition where the immune system becomes overactive. Researchers want to collect medical data and blood samples to better understand HLH and find better ways to diagnose and treat it.
This trial looks at how people with lymphoma-related hemophagocytic lymphohistiocytosis (HLH) respond to treatment. It aims to better describe expected outcomes and who benefits most, which may help guide future care.
This trial tests whether a short course of two medicines, dexamethasone (a steroid) and intravenous immunoglobulin (antibodies from donated blood), can help treat a rare condition called hemophagocytic lymphohistiocytosis (HLH) that is triggered by an infection. It may help control the body's overactive immune response and improve organ function.
This study follows adults who have findings that suggest HLH, a serious immune problem. It may help doctors better understand the condition by tracking patients over time and comparing symptoms and test results.
This study is looking at people with advanced liver cancer (HCC) that cannot be removed by surgery. Researchers want to see if certain markers in your blood or tumor can help predict how well you respond to a combination of chemotherapy delivered directly to the liver and immunotherapy. If you join, you will receive the planned treatment and provide additional blood and tissue samples for analysis.
Hear when a new Hepatic Insufficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.